You are here: Industry Insights > Market News > Glenmark gets tentative approval from US FDA for Axitinib Tablets, 1 mg and 5 mg

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Glenmark gets tentative approval from US FDA for Axitinib Tablets, 1 mg and 5 mg

expresspharmaDecember 02, 2020

Tag: Glenmark , Axitinib Tablets , FDA , Inlyta Tablets

Favorites

Glenmark Pharmaceuticals has received tentative approval by the United States Food & Drug Administration (US FDA) for Axitinib Tablets, 1 mg and 5 mg, the generic version of Inlyta Tablets, 1 mg and 5 mg, of PF Prism C.V.

According to IQVIATM sales data for the 12 month period ending October 2020, the Inlyta Tablets, 1 mg and 5 mg market2 achieved annual sales of approximately $518.8 million*.

Glenmark’s current portfolio consists of 166 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

Previous:Lupin gets US FDA approval for Penicillamine Tablets

Next:AstraZeneca’s heart failure treatment Forxiga gets approval in Japan

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

Glenmark gets tentative approval from US FDA for Axitinib Tablets, 1 mg and 5 mg | Pharmasources.com

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Glenmark gets tentative approval from US FDA for Axitinib Tablets, 1 mg and 5 mg

Related News

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

You may like